Amenorrhea has not been reported as an adverse event in fingolimod phase III clinical trials in patients with multiple sclerosis (MS) with either 0.5 mg or 1.25 mg dosages. Here we report three cases of young women with MS who developed amenorrhea within 6 months of initiation of fingolimod. They experienced irregularities in their menstrual cycles in the first 3 months, which progressed to amenorrhea by 5th or 6th month. Gynecology evaluations showed no other etiologies. Menses returned to baseline after discontinuation of fingolimod for 2–3 months. Amenorrhea could be associated with fingolimod in the first year. Future surveillance is advised to determine the incidence rate of this adverse event.
ChunJHartungHP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol2010; 33: 91–101.
3.
CohenJABarkhofFComiG. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med2010; 362: 402–415.
4.
KapposLRadueEWO’ConnorP. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med2010; 362: 387–401.
5.
BrinkmannVBaumrukerT. Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr Opin Pharmacol2006; 6: 244–250.
6.
Master-HunterTHeimanDL. Amenorrhea: Evaluation and treatment. Am Fam Physician2006; 73: 1374–1382.
7.
MeethalSVLiuTChanHW. Identification of a regulatory loop for the synthesis of neurosteroids: A steroidogenic acute regulatory protein-dependent mechanism involving hypothalamic-pituitary-gonadal axis receptors. J Neurochem2009; 110: 1014–1027.
8.
TeranEEscuderoCViveroS. Physiological changes in platelet aggregation and nitric oxide levels during menstrual cycle in healthy women. Nitric Oxide2002; 7: 217–220.
9.
GoldenNHCarlsonJL. The pathophysiology of amenorrhea in the adolescent. Ann N Y Acad Sci2008; 1135: 163–178.
10.
MarsolaisDRosenH. Chemical modulators of sphingosine-1-phosphate receptor as barrier-oriented therapeutic molecules. Nat Rev Drug Discov2011; 8: 297–307.
KhatriBBarkhofFComiG. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: A randomised extension of the TRANSFORMS study. Lancet Neurol2011; 10: 520–529.
